Shyam Kalavar

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer”.

FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0991

N/A

2.9DataRank · unranked

108 citations

Mirat Shah, Gwynn Ison, Haley Gittleman, Mallorie H. Fiero, Ankit Shah +20 more

US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA / AKT1 / PTEN Alterations

Journal of Clinical Oncology(2024)10.1200/jco.24.00427

N/A

0.978DataRank · unranked

41 citations

James Buturla, Christy Osgood, Xin Gao, Wei Chen, Tiffany K. Ricks +14 more

FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3699

N/A

0DataRank · unranked

47 citations

Erin Larkins, A. K. Sinha, Pallavi S. Mishra‐Kalyani, Samina Jafri, Shyam Kalavar +6 more

FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA -Mutated Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0883

N/A

0DataRank · unranked

0 citations

Dow-Chung Chi, Sundeep Agrawal, Hee‐Koung Joeng, Sarah Kim-McOlash, Wimolnut Manheng +17 more